FAST: Evaluation of Function And Satisfaction of UbrogepanT-treated Migraine Patients in Canada (FAST): Prospective, Observational, Real-world Study
Summary
What is the real-world effectiveness of ubrogepant for migraine treatment in Canada?
This is a prospective, observational, multicenter study to assess the effectiveness of ubrogepant for the acute treatment of migraine attacks in routine clinical practice in Canada. Approximately 167 adults (≥ 18 years of age) prescribed ubrogepant by their physician for the treatment of migraine will be enrolled.
The overall study duration will be approximately 12 weeks and will consist of 2 site visits at baseline (enrollment) (Visit 1/Day 1) and Week 12 (Visit 4/end of study). Telephone visits will occur at Weeks 4 (Visit 2) and 8 (Visit 3).
Eligibility
Eligible ages: 18 to 100
Accepts healthy participants: Yes
Inclusion criteria:
1. Able to give voluntary informed consent before starting any study-related assessments or procedures.
2. Adults ≥ 18 years of age at time of informed consent.
3. At least 1-year history of migraine with or without aura.
4. History of experiencing at least 3 migraine attacks per month with moderate to severe symptoms.
5. Prescribed ubrogepant by their physician for the acute treatment of migraine prior to study participation.
6. Willing and able to comply with the requirements of the study.
7. Has access to an electronic device (mobile phone, tablet, laptop, etc.) with internet access.
Exclusion criteria:
Exclusion criteria:
1. Previously exposed to a ubrogepant or rimegepant as routine therapy or through a clinical trial.
2. Known contraindication to ubrogepant.
3. Pregnant or planning to be pregnant or of childbearing potential not using contraception.
4. Enrolled in any interventional studies that may include investigational compounds for migraine or non-AbbVie observational studies.
5. History or current evidence of any condition that might interfere with their ability to comply with the study requirements, in the opinion of the investigator.
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
CHAMP (Calgary Headache Assessment & Management Program) Research Office Outpatient Neurology, 5th Floor Clinic 5E South Health Campus
Principal investigator:
Farnaz Amoozegar
Clinical trial:
Yes
REB-ID:
REB24-1948